| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $225K | — | — |
| R&D Expense | $14.8M | — | -29.6% |
| SG&A Expense | $5.4M | — | -15.7% |
| Operating Income | -$20.1M | — | +27.1% |
| Pre-tax Income | -$19.3M | — | +28.3% |
| Income Tax | $0 | — | — |
| Net Income | -$19.3M | — | +28.3% |
| EPS (Basic) | -$0.09 | — | +62.5% |
| EPS (Diluted) | -$0.09 | — | +62.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $80.9M | -19.6% | +50.4% |
| Accounts Receivable | $10.6M | — | — |
| Current Assets | $96.6M | -8.5% | +2.2% |
| Total Assets | $135.1M | -8.1% | -6.2% |
| Current Liabilities | $16.8M | +8.7% | +18.6% |
| Total Liabilities | $28.9M | +22.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$19.2M | — | +16.8% |
| Capital Expenditures | $11K | — | -97.1% |
| Investing Cash Flow | -$11K | — | -100.0% |
| Financing Cash Flow | -$415K | — | -100.8% |
| Free Cash Flow | -$19.2M | — | +18.1% |
| +17.6% |
| Stockholders' Equity | $106.2M | -13.9% | -11.1% |